Logo

Clinical Data Makes Milestone Payment to Germany's Merck

Dec 10, 2007

NEW YORK (GenomeWeb News) - Clinical Data said today it has paid out 135,146 of its shares to Merck KGaA as a milestone payment after successfully completing a Phase III study of the German firm’s Vilazodone drug.

Clinical Data’s shares closed most recently at $24.22.

Clinical Data acquired the rights to antidepressant Vilazodone in 2004 and is developing the drug along with a genetic test that will help doctors match patients with a treatment that is most likely to work in the first instance.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.